| Description | KR30031 is a novel P-glycoprotein inhibitor with potential anticancer activity. KR30031 is a verapamil analog with fewer cardiovascular effects. The ability of KR-30031 to reduce this efflux transport is equal to that of verapamil, a well-known P-glycoprotein inhibitor. The bioavailability of paclitaxel could be enhanced by coadministration of a P-glycoprotein inhibitor, KR-30031. |
| molecular weight | 438.56 |
| Molecular formula | C26H34N2O4 |
| CAS | 205535-74-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |